| ISIN | LU2492015610 |
|---|---|
| Valor Number | 120608809 |
| Bloomberg Global ID | |
| Fund Name | Kieger Sustainable Healthcare Fund Class A CHF (H) Accumulating |
| Fund Provider |
Kieger AG
Kieger AG Limmatstrasse 264, CH-8005 Zürich Phone: +41 44 444 18 44 Web: https://kieger.com/ E-Mail: info@kieger.com |
| Fund Provider | Kieger AG |
| Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
| Distributor(s) | |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
| Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
| Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related issuers worldwide (including Emerging Markets). The Sub-Fund aims to have a positive impact on society by investing in sustainable companies with current or future activities positively contributing to good health and well-being. The objective is reached by investing in innovative companies with differentiated products and/or services that are leaders in sustainability as identified through a proprietary sustainability framework developed by the Investment Manager. |
| Peculiarities |
| Current Price * | 99.74 CHF | 11.12.2025 |
|---|---|---|
| Previous Price * | 98.69 CHF | 10.12.2025 |
| 52 Week High * | 104.77 CHF | 05.02.2025 |
| 52 Week Low * | 89.41 CHF | 07.08.2025 |
| NAV * | 99.74 CHF | 11.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 187,637,280 | |
| Unit/Share Assets *** | 1,104,746 | |
| Trading Information SIX | ||
| YTD Performance | +2.95% |
31.12.2024 - 11.12.2025
31.12.2024 11.12.2025 |
|---|---|---|
| 1 month | +0.45% |
11.11.2025 - 11.12.2025
11.11.2025 11.12.2025 |
| 3 months | +4.13% |
11.09.2025 - 11.12.2025
11.09.2025 11.12.2025 |
| 6 months | +2.54% |
11.06.2025 - 11.12.2025
11.06.2025 11.12.2025 |
| 1 year | -2.05% |
11.12.2024 - 11.12.2025
11.12.2024 11.12.2025 |
| 2 years | +2.82% |
11.12.2023 - 11.12.2025
11.12.2023 11.12.2025 |
| 3 years | -1.14% |
12.12.2022 - 11.12.2025
12.12.2022 11.12.2025 |
| 5 years | -0.26% |
04.08.2022 - 11.12.2025
04.08.2022 11.12.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eli Lilly and Co | 6.36% | |
|---|---|---|
| UnitedHealth Group Inc | 5.85% | |
| Abbott Laboratories | 5.75% | |
| AstraZeneca PLC | 5.68% | |
| Novartis AG Registered Shares | 5.51% | |
| Roche Holding AG | 5.40% | |
| Boston Scientific Corp | 4.02% | |
| Vertex Pharmaceuticals Inc | 4.00% | |
| Novo Nordisk AS Class B | 3.53% | |
| Danaher Corp | 3.44% | |
| Last data update | 30.09.2025 | |
| TER | |
|---|---|
| TER date | |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.85% |
| Ongoing Charges *** | 1.34% |
|
SRRI ***
|
|
| SRRI date *** | 30.04.2024 |